Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788374 | 1.00 | IRAK4 (0.37) | IRAK4BRD4LRRK2CRHR1 | |
| SCHEMBL5787990 | 0.83 | BRD4 (0.35) | IRAK4BRD4CRHR1 | |
| SCHEMBL5787986 | 0.83 | BRD4 (0.35) | IRAK4BRD4CRHR1 | |
| SCHEMBL5707847 | 0.71 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL5844093 | 0.70 | SOS1 (0.36) | IRAK4LRRK2CRHR1 | |
| SCHEMBL5610816 | 0.70 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL5787033 | 0.69 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL5787155 | 0.69 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL6305307 | 0.65 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL8522874 | 0.65 | LRRK2 (0.38) | IRAK4LRRK2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC | 2005-01-13 | — | — | US | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | claimed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CHEN YUHPYNG L (US) | 2001-07-12 | — | — | US | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| EP-0923582-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998008847-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-03-05 | — | — | WO | claimed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | IRAK4 3119/4885BRD4 3449/4885LRRK2 2559/4885 |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, ABCG2 | IRAK4 4444/4885BRD4 199/4885LRRK2 1537/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | IRAK4 3398/4885BRD4 2521/4885LRRK2 1245/4885 |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | CRH, GHSR, GHRHR | IRAK4 4005/4885BRD4 2805/4885LRRK2 4191/4885 |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, CYP3A5 | IRAK4 4406/4885BRD4 281/4885LRRK2 1935/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | IRAK4 3245/4885BRD4 3810/4885LRRK2 3038/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | IRAK4 3398/4885BRD4 2521/4885LRRK2 1245/4885 |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CYP2D6, CYP2B6, CYP3A5 | IRAK4 4381/4885BRD4 427/4885LRRK2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.